Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(03): 354-356
DOI: 10.4103/ijmpo.ijmpo_110_16
Case Report

Acute Lymphoblastic Leukemia as Secondary Malignancy in a Case of Ewing’s Sarcoma on Treatment

Satyam Satyarth
Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
,
Sonia Parikh
Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
,
Asha Anand
Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
,
Jyoti Sawhney
Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
,
Harsha Panchal
Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
,
Apurva Patel
Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
,
Sandeep Shah
Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

The survival of Ewing's sarcoma (ES) has improved due to advances in both local and systemic therapy. This has given rise to an increased detection of second malignant neoplasms which can be in the form of solid tumors and hematological malignancies. The most common hematological malignancies are acute myeloid leukemia/myelodysplastic syndrome. Acute lymphoblastic leukemia (ALL) is relatively uncommon in occurrence in this setting. Furthermore, the average refractory period for hematological malignancies varies from 3 to 5 years. We report a case of a young female who developed ALL while on adjuvant therapy for ES.

Keywords

Acute lymphoblastic leukemia - Ewing's sarcoma - secondary malignancy


Publication History

Article published online:
04 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Phillips RF, Higinbotham NL. The curability of Ewing's endothelioma of bone in children. J Pediatr 1967;70:391-7.
  • 2 Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
  • 3 Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Körholz D, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000;11:1451-62.
  • 4 Sultan I, Rihani R, Hazin R, Rodriguez-Galindo C. Second malignancies in patients with Ewing sarcoma family of tumors: A population-based study. Acta Oncol 2010;49:237-44.
  • 5 Kuttesch JF Jr., Wexler LH, Marcus RB, Fairclough D, Weaver-McClure L, White M, et al. Second malignancies after Ewing's sarcoma: Radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996;14:2818-25.
  • 6 Bacci G, Longhi A, Barbieri E, Ferrari S, Mercuri M, Briccoli A, et al. Second malignancy in 597 patients with Ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. J Pediatr Hematol Oncol 2005;27:517-20.
  • 7 Fuchs B, Valenzuela RG, Petersen IA, Arndt CA, Sim FH. Ewing's sarcoma and the development of secondary malignancies. Clin Orthop Relat Res 2003;(415):82-9.
  • 8 Wagner LM, Neel MD, Pappo AS, Merchant TE, Poquette CA, Rao BN, et al. Fractures in pediatric Ewing sarcoma. J Pediatr Hematol Oncol 2001;23:568-71.
  • 9 Paulino AC, Fowler BZ. Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol 2005;22:89-101.
  • 10 McLean TW, Hertel C, Young ML, Marcus K, Schizer MA, Gebhardt M, et al. Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: The Dana-Farber Cancer Institute/Children's Hospital experience. J Pediatr Hematol Oncol 1999;21:486-93.
  • 11 Hawkins MM, Wilson LM, Burton HS, Potok MH, Winter DL, Marsden HB, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996;88:270-8.
  • 12 Goldsby R, Burke C, Nagarajan R, Zhou T, Chen Z, Marina N, et al. Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: Follow-up of a Children's Oncology Group cohort. Cancer 2008;113:2597-604.
  • 13 Bhatia S, Krailo MD, Chen Z, Burden L, Askin FB, Dickman PS, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood 2007;109:46-51.
  • 14 Bacci G, Toni A, Avella M, Manfrini M, Sudanese A, Ciaroni D, et al. Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy. Cancer 1989;63:1477-86.
  • 15 Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, et al. Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol 2001;12:1619-30.
  • 16 Rossbach HC, Chamizo W, Walling AK, Grana NH, Washington K, Barbosa JL. Ki-1+large-cell anaplastic lymphoma after Ewing sarcoma. J Pediatr Hematol Oncol 1999;21:50-2.
  • 17 Cope JU, Tsokos M, Miller RW. Ewing sarcoma and sinonasal neuroectodermal tumors as second malignant tumors after retinoblastoma and other neoplasms. Med Pediatr Oncol 2001;36:290-4.
  • 18 Spunt SL, Rodriguez-Galindo C, Fuller CE, Harper J, Krasin MJ, Billups CA, et al. Ewing sarcoma-family tumors that arise after treatment of primary childhood cancer. Cancer 2006;107:201-6.
  • 19 Ceha HM, Balm AJ, de Jong D, van 't Veer LJ. Multiple malignancies in a patient with bilateral retinoblastoma. J Laryngol Otol 1998;112:189-92.
  • 20 Helton KJ, Fletcher BD, Kun LE, Jenkins JJ 3rd, Pratt CB. Bone tumors other than osteosarcoma after retinoblastoma. Cancer 1993;71:2847-53.
  • 21 Mittal R, Al Awadi S, Sahar O, Behbehani AM. Ewing's sarcoma as second malignant neoplasm after retinoblastoma: A case report. Med Princ Pract 2008;17:84-5.
  • 22 Mohney BG, Robertson DM, Schomberg PJ, Hodge DO. Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am J Ophthalmol 1998;126:269-77.
  • 23 Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 1998;16:3628-33.
  • 24 Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995;86:3542-52.
  • 25 Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993;82:3705-11.
  • 26 Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993;329:909-14.